Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,571,081 shares of the biopharmaceutical company’s stock after buying an additional 65,623 shares during the quarter. Geode Capital Management LLC owned about 1.70% of Ultragenyx Pharmaceutical worth $87,296,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. nVerses Capital LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth about $33,000. UMB Bank n.a. boosted its position in Ultragenyx Pharmaceutical by 58.1% during the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 352 shares during the last quarter. True Wealth Design LLC purchased a new stake in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $43,000. Values First Advisors Inc. acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at $56,000. Finally, Nomura Asset Management Co. Ltd. purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $93,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. JPMorgan Chase & Co. reduced their target price on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Royal Bank of Canada reissued an “outperform” rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Finally, TD Cowen raised their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $87.46.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE opened at $43.47 on Friday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37. The company’s fifty day moving average is $49.75 and its two-hundred day moving average is $49.23. The stock has a market capitalization of $4.01 billion, a price-to-earnings ratio of -6.72 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.05. The firm had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm’s revenue for the quarter was up 42.3% on a year-over-year basis. During the same period last year, the company earned ($2.23) earnings per share. Sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 8,273 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the completion of the sale, the chief executive officer now owns 2,195,712 shares of the company’s stock, valued at $109,785,600. This represents a 0.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Howard Horn sold 7,465 shares of the stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 7.48 % decrease in their position. The disclosure for this sale can be found here. 5.80% of the stock is owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.